Sign in
CompletedPhase 2

Switching Regimen in Treating Cirrhotic HCV GT1b Subjects

Key facts

Who runs it
Humanity and Health Research Centre
Where
China2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
138 people enrolled
Started
15 May 2015
Ended
31 Oct 2024
Type of study
Interventional, 8 groups
Treatments tested
  • PR4 + LDV/SOF + ASV 4 wk
  • PR4 + LDV/SOF + SMV 4 wk
  • PR4 + LDV/SOF + ASV 6 wk
  • PR4 + LDV/SOF + SMV 6 wk
  • PR4 + LDV/SOF + ASV 8 wk
  • PR4 + LDV/SOF + SMV 8 wk
  • PR4 + LDV/SOF + ASV 12 wk
  • PR4 + LDV/SOF + SMV 12 wk
Record updated
26 March 2025

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Individuals with chronic HCV GT1b infection
  • HCV RNA ≥ 10000 IU/mL at screening
  • Received 4 weeks pegylated interferon plus ribavirin (PR4) therapy and are intolerant to PR4
  • Cirrhosis determination; a liver biopsy may be required
  • Use of highly effective contraception methods if female of childbearing potential or sexually active male

Who cannot take part

  • Active or recent history (≤ 1 year) of drug or alcohol abuse
  • HIV or HBV co-infection
  • History or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study, or interfere with the subject's participation for the full duration of the study, such that it is not in the best interest of the subject to participate
  • Pregnant or nursing female or male with pregnant female partner
  • Hematologic or biochemical parameters at Screening outside the protocol- specified requirements

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a prospective, randomized study to evaluate the efficacy and safety of switching treatment from Peg-interferon and Ribavirin to direct-acting antiviral agents in Chinese with CHC genotype 1b infection, who are interferon/ribavirin-intolerant.

The 8 groups in the trial

  • PR4 + LDV/SOF + ASV 4 wkTreatment being tested

    Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA \<25 IU/ml by week 2 will receive LDV/SOF + ASV for 4 weeks.

  • PR4 + LDV/SOF + SMV 4 wkTreatment being tested

    Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA \<25 IU/ml by week 2 will receive LDV/SOF + SMV for 4 weeks.

  • PR4 + LDV/SOF + ASV 6 wkTreatment being tested

    Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA \<25 IU/ml by week 4 will receive LDV/SOF + ASV for 6 weeks.

  • PR4 + LDV/SOF + SMV 6 wkTreatment being tested

    Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA \<25 IU/ml by week 4 will receive LDV/SOF + SMV for 6 weeks.

  • PR4 + LDV/SOF + ASV 8 wkTreatment being tested

    Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA \> 2 log drop but ≥25 IU/ml by week 4 will receive LDV/SOF + ASV for 8 weeks.

  • PR4 + LDV/SOF + SMV 8 wkTreatment being tested

    Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA \> 2 log drop but ≥25 IU/ml by week 4 will receive LDV/SOF + SMV for 8 weeks.

  • PR4 + LDV/SOF + ASV 12 wkTreatment being tested

    Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA \<2 log drop by week 4 will receive LDV/SOF + ASV for 12 weeks.

  • PR4 + LDV/SOF + SMV 12 wkTreatment being tested

    Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA \<2 log drop by week 4 will receive LDV/SOF + SMV for 12 weeks.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Safety of Switching From Pegylated Interferon/Ribavirin (PR) to Direct-acting Antiviral Agents (DAAs) for Chinese With CHC Genotype 1b Infection (SWITCH-1)
Record updated
26 March 2025